Skip to main content
Category

Treatments

ResearchTreatments

Structure-based classification predicts drug response in EGFR-mutant NSCLC

*September 2021* Epidermal growth factor receptor (EGFR) mutations typically occur in exons 18–21 and are established driver mutations in non-small cell lung cancer (NSCLC)1,2,3. Targeted therapies are approved for patients with ‘classical’ mutations and a small number of other mutations4,5,6. However, effective therapies have not been identified for additional EGFR mutations. Furthermore,…
laurabbook@gmail.com
November 11, 2021
ResearchTreatments

Highlights in Lung Cancer From ESMO 2021

*September 2021* Dr. Pasi Jänne, MD, PhD, discusses promising studies from the meeting in this video. Transcript: A couple of them include the DESTINY-Lung trial, which was the trial of trastuzumab deruxtecan , a HER2 antibody drug conjugate in patients with HER2 mutant lung cancer. So this is a subset of…
laurabbook@gmail.com
November 10, 2021